Babu Boga, Vice President of Medicinal Chemistry and Xiang Li, President of the Chemical Division at BioDuro, explore the advantages of a unified FBDD workflow. The pharmaceutical industry constantly seeks innovative methods to identify novel therapeutic agents. Traditional high-throughput screening (HTS) often faces challenges like high false-positive rates and limited chemical diversity. Fragment-based drug discovery […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!